



Society for Immunotherapy of Cancer (SITC) 2021, Hybrid Meeting; Washington, D.C.: Eisai Inc. Sponsored Research

Please see the listing of Eisai Inc. sponsored research presented at SITC 2021 below and refer to the Congress Links section available on our Medical Information website which may include additional information.

ENDOMETRIAL CARCINOMA

Makker V, Aghajanian, Cohn AL, et al. Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma: Long-term Efficacy and Safety Update from a Phase 1b/2 Study. Poster presented at the Society for Immunotherapy of Cancer (SITC) 2021; November 10-14, 2021; Hybrid Meeting; Washington, D.C.

RENAL CELL CARCINOMA

Choueiri TK, Plimack E, Powles T, et al. Phase 3 Study of Pembrolizumab + Belzutifan + Lenvatinib or Pembrolizumab/Quavonlimab + Lenvatinib Versus Pembrolizumab + Lenvatinib as First-line Treatment for Advanced Renal Cell Carcinoma. Poster presented at the Society for Immunotherapy of Cancer (SITC) 2021; November 10-14, 2021; Hybrid Meeting; Washington, D.C.

NON-SMALL CELL LUNG CANCER

Gutierrez M, Lam W-S, Hellmann MD, et al. KEYNOTE-495/KeyImPaCT: Interim Analysis of a Randomized, Biomarker-Directed, Phase 2 Trial of Pembrolizumab-Based Combination Therapy for Non-Small Cell Lung Cancer (NSCLC). Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 2021; November 10-14, 2021; Hybrid Meeting; Washington, D.C.

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the publication(s) listed above, please submit your request via www.eisaimedicalinformation.com/oncology/medicalinquiry or the submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_oncmedinfo@eisai.com or call 1-888-274-2378.